☰

Jon S. Zawistowski, Ph.D. - Publications

Affiliations: 
2005 Duke University, Durham, NC 
Area:
Genetics, Molecular Biology
Tree Info Similar researchers PubMed Report error

29 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Goulet DR, Foster JP, Zawistowski JS, Bevill SM, Noel MP, Olivares-Quintero JF, Sciaky N, Singh D, Santos C, Pattenden SG, Davis IJ, Johnson GL. Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer. Molecular Cancer Research : McR. PMID 32753473 DOI: 10.1158/1541-7786.Mcr-19-1011  0.37
2019 Bevill SM, Olivares-Quintero JF, Sciaky N, Golitz BT, Singh D, Beltran AS, Rashid NU, Stuhlmiller TJ, Hale A, Moorman NJ, Santos CM, Angus SP, Zawistowski JS, Johnson GL. GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer. Molecular Cancer Research : McR. PMID 31000582 DOI: 10.1158/1541-7786.Mcr-18-1121  0.327
2018 Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, ... ... Zawistowski JS, et al. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. Plos One. 13: e0197350. PMID 29897904 DOI: 10.1371/Journal.Pone.0197350  0.327
2018 Collins KAL, Stuhlmiller TJ, Zawistowski JS, East MP, Pham TT, Hall CR, Goulet DR, Bevill SM, Angus SP, Velarde SH, Sciaky N, Oprea TI, Graves LM, Johnson GL, Gomez SM. Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer. Oncotarget. 9: 15480-15497. PMID 29643987 DOI: 10.18632/Oncotarget.24337  0.34
2018 Zawistowski J, Bevill S, Johnson GL. Abstract IA23: Enhancer remodeling in response to MEK inhibition in TNBC Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-Ia23  0.382
2018 Bevill SM, Sciaky N, Golitz BT, Rashid NU, Zawistowski JS, Johnson GL. Abstract B34: Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-B34  0.356
2017 Bevill SM, Zawistowski JS, Johnson GL. Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer. Molecular & Cellular Oncology. 4: e1300622. PMID 29209639 DOI: 10.1080/23723556.2017.1300622  0.363
2017 Stuhlmiller TJ, Zawistowski JS, Chen X, Sciaky N, Angus SP, Hicks ST, Parry TL, Huang W, Beak JY, Willis MS, Johnson GL, Jensen BC. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition. Journal of the American Heart Association. 6. PMID 29051215 DOI: 10.1161/Jaha.117.006635  0.341
2017 Angus SP, Zawistowski JS, Johnson GL. Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer. Annual Review of Pharmacology and Toxicology. PMID 28934561 DOI: 10.1146/Annurev-Pharmtox-010617-052954  0.387
2017 Mobley RJ, Raghu D, Duke LD, Abell-Hart K, Zawistowski JS, Lutz K, Gomez SM, Roy S, Homayouni R, Johnson GL, Abell AN. MAP3K4 Controls the Chromatin Modifier HDAC6 during Trophoblast Stem Cell Epithelial-to-Mesenchymal Transition. Cell Reports. 18: 2387-2400. PMID 28273454 DOI: 10.1016/J.Celrep.2017.02.030  0.317
2017 Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, et al. Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex. Cancer Discovery. PMID 28108460 DOI: 10.1158/2159-8290.Cd-16-0653  0.348
2016 Stuhlmiller TJ, Miller SM, Zawistowski JS, Duncan JS, Angus SP, Granger DA, Reuther RA, Collins KAL, Shawn GM, Kuan P, Chen X, Sciaky N, Johnson GL. Abstract B25: BET bromodomain inhibition targets adaptive responses to lapatinib in HER2-positive breast cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B25  0.411
2016 Zawistowski JS, Miller SM, Goulet DR, Stuhlmiller TJ, Singh D, Sciaky N, Velarde SH, Angus SP, Johnson GL. Abstract B24: Triple-negative breast cancer adaptive response to MEK inhibition is regulated by the induction of super-enhancers Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B24  0.374
2016 Miller SM, Zawistowski JS, Stuhlmiller TJ, Sciaky N, Santos CM, Darr DB, Johnson GL. Abstract B21: Suppression of adaptive resistance mechanisms to trametinib by inhibition of BET bromodomains in TNBC Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B21  0.385
2015 Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, et al. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. Cell Reports. 11: 390-404. PMID 25865888 DOI: 10.1016/J.Celrep.2015.03.037  0.365
2014 Zawistowski JS, Graves LM, Johnson GL. Assessing adaptation of the cancer kinome in response to targeted therapies. Biochemical Society Transactions. 42: 765-9. PMID 25109955 DOI: 10.1042/Bst20130274  0.363
2014 Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2516-22. PMID 24664307 DOI: 10.1158/1078-0432.Ccr-13-1081  0.392
2013 Jordan NV, Prat A, Abell AN, Zawistowski JS, Sciaky N, Karginova OA, Zhou B, Golitz BT, Perou CM, Johnson GL. SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. Molecular and Cellular Biology. 33: 3011-25. PMID 23716599 DOI: 10.1128/Mcb.01443-12  0.363
2013 Zawistowski JS, Nakamura K, Parker JS, Granger DA, Golitz BT, Johnson GL. MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition. Molecular and Cellular Biology. 33: 2260-74. PMID 23530058 DOI: 10.1128/Mcb.00269-13  0.308
2012 Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 149: 307-21. PMID 22500798 DOI: 10.1016/J.Cell.2012.02.053  0.343
2012 Midland AA, Whittle MC, Duncan JS, Abell AN, Nakamura K, Zawistowski JS, Carey LA, Earp HS, Graves LM, Gomez SM, Johnson GL. Defining the expressed breast cancer kinome. Cell Research. 22: 620-3. PMID 22310242 DOI: 10.1038/Cr.2012.25  0.324
2008 Nakamura K, Zawistowski JS, Hughes MA, Sexton JZ, Yeh LA, Johnson GL, Scott JE. Homogeneous time-resolved fluorescence resonance energy transfer assay for measurement of Phox/Bem1p (PB1) domain heterodimerization. Journal of Biomolecular Screening. 13: 396-405. PMID 18480472 DOI: 10.1177/1087057108318281  0.355
2006 Plummer NW, Squire TL, Srinivasan S, Huang E, Zawistowski JS, Matsunami H, Hale LP, Marchuk DA. Neuronal expression of the Ccm2 gene in a new mouse model of cerebral cavernous malformations. Mammalian Genome : Official Journal of the International Mammalian Genome Society. 17: 119-28. PMID 16465592 DOI: 10.1007/S00335-005-0098-8  0.711
2005 Plummer NW, Zawistowski JS, Marchuk DA. Genetics of cerebral cavernous malformations. Current Neurology and Neuroscience Reports. 5: 391-6. PMID 16131422 DOI: 10.1007/S11910-005-0063-7  0.717
2005 Zawistowski JS, Stalheim L, Uhlik MT, Abell AN, Ancrile BB, Johnson GL, Marchuk DA. CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Human Molecular Genetics. 14: 2521-31. PMID 16037064 DOI: 10.1093/Hmg/Ddi256  0.668
2004 Plummer NW, Gallione CJ, Srinivasan S, Zawistowski JS, Louis DN, Marchuk DA. Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. The American Journal of Pathology. 165: 1509-18. PMID 15509522 DOI: 10.1016/S0002-9440(10)63409-8  0.706
2003 Liquori CL, Berg MJ, Siegel AM, Huang E, Zawistowski JS, Stoffer T, Verlaan D, Balogun F, Hughes L, Leedom TP, Plummer NW, Cannella M, Maglione V, Squitieri F, Johnson EW, et al. Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. American Journal of Human Genetics. 73: 1459-64. PMID 14624391 DOI: 10.1086/380314  0.721
2003 Marchuk DA, Srinivasan S, Squire TL, Zawistowski JS. Vascular morphogenesis: tales of two syndromes. Human Molecular Genetics. 12: R97-112. PMID 12668602 DOI: 10.1093/Hmg/Ddg103  0.641
2002 Zawistowski JS, Serebriiskii IG, Lee MF, Golemis EA, Marchuk DA. KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Human Molecular Genetics. 11: 389-96. PMID 11854171 DOI: 10.1093/Hmg/11.4.389  0.596
Show low-probability matches.